Obesity Clinical Trial
Official title:
Food Supplementation Interventions to Improve Weight Loss for Adults With Food Insecurity and Obesity
Verified date | May 2024 |
Source | University of Pennsylvania |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a 3-group, parallel design, randomized controlled trial (RCT) in 105 adults with obesity and food insecurity that will compare BWL-Alone (including standard-of-care referral and connection with community food resources; n=35) to BWL plus food supplementation with either food vouchers (BWL+VOUCHER; n=35) or home-delivered, medically tailored groceries consistent with BWL recommendations (BWL+HOME; n=35). All groups will have BWL treatment provided for 24 weeks per clinical guidelines. Food vouchers and HOME will be provided for 24 weeks of treatment. Assessments will be conducted at baseline, and weeks 12 and 24.
Status | Active, not recruiting |
Enrollment | 105 |
Est. completion date | August 1, 2024 |
Est. primary completion date | August 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Age >18 years 4. BMI >30 kg/m2 at screening visit 5. Screening positive for food insecurity using a score of >3 on the 10-item US Adult Food Security Survey Module109 6. Completion of baseline assessments 7. Ability to engage in physical activity (i.e., can walk at least 2 blocks) 8. Willing and able to provide pictures of food receipts to study team (or mail actual receipts) 9. Ability to reliably receive packages at a consistent location in a timely manner 10. Telephone or internet service to communicate with study staff 11. For females of reproductive potential: agreement to use of highly effective contraception for during study participation Exclusion Criteria: 1. Serious medical conditions (e.g., type 1 or type 2 diabetes, renal failure) that may pose a risk to the participant during intervention, cause a change in weight, or limit ability to adhere to the program's behavioral recommendations 2. Significant psychiatric conditions (e.g., active substance abuse, schizophrenia) that may pose a risk to the participant during intervention, cause a change in weight, or limit ability to adhere to the program's behavioral recommendations 3. Breastfeeding, pregnant or planning pregnancy in the next 6 months 4. Planned move from the Philadelphia area in the next 6 months 5. Weight loss of >5 kg in the previous 90 days 6. Recently began a course of or changed the dosage of medication that can cause significant weight change (±5 kg) 7. Previous or planned obesity treatment with surgery (excluding lap band if removed for >1 year) or a weight-loss device 8. Use of prescription or over the counter medications for chronic weight management in the past 3 months 9. Household member already participating in study due to potential contamination effects 10. Lack of stable residence and ability to store and prepare food |
Country | Name | City | State |
---|---|---|---|
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pennsylvania | National Institute of Nursing Research (NINR) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent initial weight loss at 24 weeks (BWL+VOUCHER and BWL+HOME vs BWL-Alone) | Comparison of BWL+VOUCHER and BWL+HOME vs BWL-Alone in weight loss (percent of initial weight) at 24 weeks. | Change from baseline to 24 weeks | |
Secondary | Percent initial weight loss at 24 weeks (BWL+HOME vs BWL+VOUCHER) | Comparison of BWL+HOME vs BWL+VOUCHER in weight loss (percent of initial weight) at 24 weeks. | Change from baseline to 24 weeks | |
Secondary | General health-related quality of life (BWL+VOUCHER and BWL+HOME vs BWL-Alone) | Change from baseline to week 24 in general health-related quality of life as assessed with the Short Form-36. Scores range from 0 (worse) to 100 (best). | Change from baseline to 24 weeks | |
Secondary | Weight-related quality of life (BWL+VOUCHER and BWL+HOME vs BWL-Alone) | Change from baseline to week 24 in weight-related quality of life as assessed with the Impact of Weight on Quality of Life-Lite. Scores range from 0 (worse) to 100 (best). | Change from baseline to 24 weeks | |
Secondary | Dietary quality as assessed by skin carotenoid levels (BWL+VOUCHER and BWL+HOME vs BWL-Alone) | Change from baseline to week 24 in skin carotenoid levels | Change from baseline to 24 weeks | |
Secondary | Dietary quality as assessed by the Healthy Eating Index (BWL+VOUCHER and BWL+HOME vs BWL-Alone) | Change from baseline to week 24 in Healthy Eating Index scores as measured with the Automated Self-Administered 24-Hour (ASA24) Dietary Assessment Tool. Scores range from 0 (worse) to 100 (best). | Change from baseline to 24 weeks | |
Secondary | General health-related quality of life (BWL+VOUCHER vs BWL+HOME) | Change from baseline to week 24 in general health-related quality of life as assessed with the Short Form-36. Scores range from 0 (worse) to 100 (best). | Change from baseline to 24 weeks | |
Secondary | Weight-related quality of life (BWL+VOUCHER vs BWL+HOME) | Change from baseline to week 24 in weight-related quality of life as assessed with the Impact of Weight on Quality of Life-Lite. Scores range from 0 (worse) to 100 (best). | Change from baseline to 24 weeks | |
Secondary | Dietary quality as assessed by skin carotenoid levels (BWL+VOUCHER vs BWL+HOME) | Change from baseline to week 24 in skin carotenoid levels | Change from baseline to 24 weeks | |
Secondary | Dietary quality as assessed by the Healthy Eating Index (BWL+VOUCHER vs BWL+HOME) | Change from baseline to week 24 in Healthy Eating Index scores as measured with the ASA24. Scores range from 0 (worse) to 100 (best). | Change from baseline to 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |